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Fibroblast Growth Factor-10 
(FGF-10) Mobilizes Lung-resident 
Mesenchymal Stem Cells and 
Protects Against Acute Lung Injury
Lin Tong1, Jian Zhou1, Linyi Rong1, Eric J. Seeley2, Jue Pan1, Xiaodan Zhu1, Jie Liu1, Qin Wang1, 
Xinjun Tang1, Jieming Qu3, Chunxue Bai1,4 & Yuanlin Song1,5,6
FGF-10 can prevent or reduce lung specific inflammation due to traumatic or infectious lung injury. 
However, the exact mechanisms are poorly characterized. Additionally, the effect of FGF-10 on 
lung-resident mesenchymal stem cells (LR-MSCs) has not been studied. To better characterize the 
effect of FGF-10 on LR-MSCs, FGF-10 was intratracheally delivered into the lungs of rats. Three 
days after instillation, bronchoalveolar lavage was performed and plastic-adherent cells were 
cultured, characterized and then delivered therapeutically to rats after LPS intratracheal instillation. 
Immunophenotyping analysis of FGF-10 mobilized and cultured cells revealed expression of the 
MSC markers CD29, CD73, CD90, and CD105, and the absence of the hematopoietic lineage markers 
CD34 and CD45. Multipotency of these cells was demonstrated by their capacity to differentiate into 
osteocytes, adipocytes, and chondrocytes. Delivery of LR-MSCs into the lungs after LPS injury reduced 
the inflammatory response as evidenced by decreased wet-to-dry ratio, reduced neutrophil and 
leukocyte recruitment and decreased inflammatory cytokines compared to control rats. Lastly, direct 
delivery of FGF-10 in the lungs of rats led to an increase of LR-MSCs in the treated lungs, suggesting 
that the protective effect of FGF-10 might be mediated, in part, by the mobilization of LR-MSCs in 
lungs.
Mesenchymal stem cells (MSCs) are adult connective tissue progenitor cells with multilineage differentiation 
potential1 . In addition to bone marrow (BM), MSCs can also be isolated from adult, nonhematopoietic organs 
such as the lung2. These tissue-resident MSCs represent a reservoir of endogenous organ-specific adult progenitor 
cells with a potential role in local tissue homeostasis and repair. Potent immune-regulation and anti-inflammatory 
properties of MSCs have provoked significant interest in their application as vectors for tissue repair and cell ther-
apy. Exogenously administered MSCs have been found to ameliorate injury in various animal models, including 
bleomycin-induced pulmonary fibrosis3, endotoxin-induced acute lung injury4, papain-induced emphysema5, 
and pulmonary hypertension6, as well as cardiac7 and renal allograft rejection8, and these reparative effects appear 
to be mediated by the secretory function of MSCs, rather their direct engraftment and growth. Lung-resident 
MSCs (LR-MSCs) can be isolated from bronchoalveolar lavage (BAL) of transplanted allografts, and were shown 
to be distinct from those derived from the bone marrow9. LR-MSCs have the ability to engraft in their organ of 
origin and to communicate with locally resident epithelial cells via gap junction communications10. Furthermore, 
LR-MSCs secrete KGF, an important epithelial growth factor, suggesting that lung derived MSCs can modu-
late alveolar epithelial cells in a paracrine fashion10. Allergen sensitization and challenge is accompanied by an 
increase of MSCs resident in the lungs that may regulate inflammatory and fibrotic responses as well11.
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Fibroblast growth factor-10 (FGF-10), also known as keratinocyte growth factor-2 (KGF-2), has been 
shown to mediate epithelial-mesenchymal interactions, which are essential to lung development12–18. FGF-10 
is a 20-kDa heparin-binding protein predominantly expressed by mesenchymal cells. It binds with high affin-
ity to a spliced variant of fibroblast growth factor receptor 2-IIIb (FGFR2-IIIb), and also has a weaker affinity 
for FGFR1-IIIb15,19–22. Recently it was illustrated that FGF-10 could prevent lung injury after various stresses 
including bleomycin-induced pulmonary fibrosis23, high altitude pulmonary edema24, LPS-induced lung injury25, 
mechanical ventilation induced lung injury26 and ischemia-reperfusion lung injury27. Although the experimental 
data illustrating the protective effects of FGF-10 on lung injury are robust, the mechanism underlying these pro-
tective effects have not been fully elucidated.
In this study, we demonstrate that LR-MSCs can be easily isolated from the lower respiratory tract of rats 
pretreated with FGF-10. Additionally, we illustrate that the LR-MSCs isolated from FGF-10 pretreated rats are 
protective against LPS-induced acute lung injury. Collectively, we demonstrate for the first time the role of FGF-
10 in LR-MSCs proliferation, mobilization and the organ specific protective effects against acute lung injury.
Results
Isolation of plastic-adherent fibroblastoid cells from BAL fluid of FGF-10 pretreated lungs. 
Intratracheal instillation of FGF-10 (5 mg/kg) three days prior to inflammatory injury was demonstrated to be 
protective in models of acute lung injury23–27. To determine whether pretreatment with FGF-10 would mobilize 
MSC-like cells, FGF-10 was administered to rats and BAL fluid was collected and analyzed. Forty-eight hours 
after plating cells collected through BAL, adherent Fibroblastoid cells, which were much larger than alveolar mac-
rophages, could be seen adhering to the bottom of plastic culture flasks (Fig. 1c,d). Fibroblastoid colonies were 
observed 14 days after cells collected via BAL were plated (Fig. 1a,b). The number of colony-forming unit-fibro-
blasts (CFU-Fs) formed per 1 × 105 mononuclear cells plated varied between samples (mean, 22; range, 12–28) 
(Fig. 1e). CFU-Fs were identified in 100% (n = 15) of the BAL samples obtained from the lungs of rats pretreated 
with FGF-10. These CFU-Fs were expanded in culture by subsequent trypsinization and serial passage.
Phenotypic characteristics of BAL-derived fibroblastoid cells. CFU-Fs initially identified from the 
BAL were expanded in cell culture without morphological evidence of cellular senescence. Immunophenotyping 
for surface antigens by flow cytometry was performed on BAL-derived CFU-Fs to further characterize these 
cells. They strongly expressed CD29, CD73 and CD90 (Fig. 2), as previously described for bone marrow-derived 
MSCs28. Furthermore, these cells did not express the hematopoietic lineage markers CD34 and CD45 (Fig. 2). 
Immunofluorescence studies of these BAL-derived cells demonstrated expression of the MSC marker CD105, the 
mesenchymal cell marker vimentin and the water channel aquaporin-5 (AQP5) as previously described for bone 
marrow-derived MSCs29 (Fig. 2).
Multipotential differentiation of BAL-derived mesenchymal cells. One of defining characteristics 
of MSCs is their ability to differentiate into multiple mesenchymal lineages. Thus we determined the ability of 
BAL-derived mesenchymal cells to differentiate into specific connective tissue cell types. Mesenchymal cells (at 
passages 3–5) were studied under defined culture conditions to induce osteocytic, adipocytic, and chondrocytic 
differentiation (as described in Methods). The ability of BAL-derived mesenchymal cells to differentiate into 
osteocytes was demonstrated by staining for extracellular mineralization in cells following osteogenic stimulation 
(Fig. 3a), and was confirmed by inmunofluorescent staining of osteocalcin (Fig. 3b). Osteocytic differentiation 
was absent in control untreated cells. Adipocytic differentiation was demonstrated in cells stimulated with insu-
lin and other adipogenic stimuli by accumulation of lipid-rich vacuoles that stained positively with oil red O 
(Fig. 3c), and was confirmed by immunofluorescent staining of FABP4 (Fig. 3d). No oil red O staining was seen 
in the control cells. Pelleted micromasses of cells treated with chondrocytic stimulation underwent chondrocytic 
differentiation, as evidenced by the presence of the extracellular matrix proteoglycan aggrecan (Fig. 3f). These 
studies suggest that BAL-derived mesenchymal cells are capable of differentiating into multiple connective tissue 
cell lineages.
Microarray data of LR-MSCs. To determine whether the gene expression profiles in MSCs from the FGF-
10 treated lungs are different from those derived from the bone marrow, we compared the transcriptome of 
MSCs from these two sources by Affymetrix analysis (GEO accession: GSE68243). Gene Ontology (GO) analy-
sis showed that compared to BM-MSCs, BAL-derived MSCs had increased expression of genes involved in cell 
adhesion, integrin-mediated signaling pathways, epithelial cell proliferation, extracellular matrix organization, 
cell migration, etc, while other transcription programs were down regulated, including the response to lipopoly-
saccharide, response to drug, cell-cell adhesion, response to hypoxia, aging, etc (Fig. 4). Pathway analysis showed 
that MAPK signaling pathways were similarly regulated in both MSC sub-types (Fig. 5).
EdU incorporation of LR-MSCs. Lung tissue-specific MSCs are present in the adult lung9. To determine 
whether the increased number of MSCs in BAL of FGF-10 pretreated lungs represent the proliferation of MSCs, 
EdU (5-ethynyl-2′ -deoxyuridine) was injected intraperitoneally in FGF-10 pretreated rats 24 hours before BAL. 
MSCs in BAL fluid were subsequently isolated, cultured for 5–7 days, then EdU incorporation was measured. 
There were about 27% EdU positive MSCs among the isolated MSCs (Fig. 6), suggesting these cells had active 
DNA synthesis during the 24-hour period prior to BAL.
With intravenous injection of FGF-10 at the same dose (5 mg/kg) or 2–3 folds higher, no LR-MSCs were found 
in BAL fluid (Fig. 1e). Furthermore, peripheral blood mononuclear cells from FGF-10 treated rats (including 
intratracheal instillation and intravenous injection) were collected and cultured. No LR-MSCs could be isolated 
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Figure 1. Isolation and characterization of fibroblastoid cells from BAL of rats pretreated with FGF-10. 
(a) Two weeks after plating of mononuclear cells obtained from BAL of FGF-10 pretreated rats, Wright-Giemsa 
staining identified the CFU-Fs. (b) An individual CFU-F with Wright-Giemsa staining. (c) Forty-eight hours 
after initial plating of mononuclear cells obtained from BAL of FGF-10 pretreated rats, fibroblastoid cells could 
be seen adherent to plastic bottom of culture flasks. (d) Electron microscopy imaging of the fibroblastoid cells 
from BAL. (e) Number of CFU-Fs formed per 1 × 105 mononuclear cells collected via BAL from rats prereated 
with intratracheal PBS (PBS i.t.), intratracheal FGF-10 (FGF-10 i.t.), or intravenous FGF-10 (FGF-10 i.v.). Each 
point corresponds to the mean ± SEM.
www.nature.com/scientificreports/
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from BAL with either route of injection. Taken together, these data suggest that FGF-10 stimulates proliferation 
of lung resident MSCs, rather than mobilizing MSCs from bone marrow.
Expression of FGF-10 receptors on MSCs. FGFR1-IIIb and FGFR2-IIIb are two receptors of FGF-10. To 
determine whether MSCs express these receptors, real-time PCR was done with primers specific to FGFR1-IIIb 
and FGFR2-IIIb, and the PCR products were sequenced to validate the specificity. It was shown that MSCs express 
the mRNAs of both receptors (Fig. 7a). Relative quantification data illustrated that FGFR2-IIIb expression is more 
abundant than FGFR1-IIIb at transcriptional level (Fig. 7b). Western blot analysis and immunofluorescence stud-
ies then confirmed that MSCs express the protein of FGFR2 on cell membrane (Fig. 7c,d).
Effects of LR-MSCs and BM-MSCs on LPS-induced acute lung injury. BM-MSCs were found to be 
protective in several models of lung injury, including LPS-induced acute lung injury30. To determine whether 
LR-MSCs derived from BAL are also protective, LR-MSCs were delivered intratracheally to the lungs 4 hours after 
LPS instillation, and measures of lung injury were assessed 24 h and 48 h after LPS challenge.
Rats receiving BM-MSCs showed a trend toward lower lung wet-to-dry ratio at 24 h. And both the BM-MSCs 
and LR-MSCs groups showed a significant reduction in wet-to-dry ratio at 48 h compared to PBS control group 
Figure 2. Immunophenotyping of BAL-derived fibroblastoid cells. Flow cytometric analysis was used 
to identify the surface antigens of BAL-derived fibroblastoid cells. These cells were predominantly positive 
for CD29, CD73 and CD90 (upper panels), and negative for the hematopoietic lineage markers CD34 and 
CD45 (middle panels). All histograms show specific mAbs in red and control isotype-specific IgGs in blue. 
Immunofluorescence staining of BAL-derived fibroblastoid cells demonstrated expression of CD105, AQP5 and 
vimentin (lower panels).
www.nature.com/scientificreports/
5Scientific RepoRts | 6:21642 | DOI: 10.1038/srep21642
Figure 3. Mesenchymal cells isolated from BAL differentiate to multiple connective tissue lineages.  
(a) Osteocytic differentiation was indicated by calcium deposition as demonstrated by alizarin red staining. 
(b) Osteocytic differentiation was confirmed by inmunofluorescent staining of osteocalcin. (c) Adipocytic 
differentiation was demonstrated by accumulation of lipid droplets that stained positively with oil red O. 
(d) Adipocytic differentiation was confirmed by inmunofluorescent staining of FABP4. (e) Chondrocytic 
differentiated cells of pelleted micromass were stained with H&E. (f) Chondrocytic differentiation was 
evidenced by the presence of the extracellular matrix proteoglycan aggrecan.
Figure 4. Gene Ontology (GO) analysis of the transcriptome revealed the functional diversity of BM-MSCs 
and BAL-derived MSCs (n = 3). (a) Compared with BM-MSCs, down-regulated functions of BAL-derived 
MSCs. (b) Compared with BM-MSCs, up-regulated functions of BAL-derived MSCs.
www.nature.com/scientificreports/
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(Fig. 8a). In addition, BAL protein, a marker of endothelial and epithelial permeability, was not significantly 
reduced in either MSCs groups at 24 h, but significantly reduced in the LR-MSCs group at 48 h compared to PBS 
control group (Fig. 8b).
Figure 5. Pathway analysis of the transcriptome revealed the signaling pathway diversity of BAL-derived 
MSCs and BM-MSCs. Red circle represent the pathway of up-regulated genes, comparing to BM-MSCs. Blue 
circle represent the pathway of down-regulated genes, comparing to BM-MSCs. Yellow circle represent the 
pathway of both up- and down-regulated genes, comparing to BM-MSCs.
Figure 6. EdU incorporation assay. EdU was injected intraperitoneally to FGF-10 pretreated rats 24 hours 
before BAL. The mononuclear cells obtained from BAL of FGF-10 pretreated rats were cultured for 5–7 days, 
and detected for EdU incorporation. There were EdU positive MSCs among the cultured BAL-derived MSCs 
(arrow).
www.nature.com/scientificreports/
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BAL studies were done at 24 and 48 h after LPS instillation to determine whether neutrophil counts were lower 
in the MSCs-treated vs. PBS-treated rats. Total cell counts and absolute neutrophil counts were not different 
among the three groups at 24 h, but were significantly decreased in the LR-MSCs group at 48 h (Fig. 8c,d). At both 
Figure 7. Expression of FGFR1-IIIb and FGFR2-IIIb in MSCs. (a) Real-time PCR was done with primers 
specific to FGFR1-IIIb and FGFR2-IIIb, and the PCR products were identified by electrophoresis (1, DNA 
marker; 2, β -actin of LR-MSCs; 3, FGFR1-IIIb of LR-MSCs; 4, FGFR2-IIIb of LR-MSCs; 5, β -actin of BM-
MSCs; 6, FGFR1-IIIb of BM-MSCs; 7, FGFR2-IIIb of BM-MSCs). (b) The relative expression level of FGFR1-
IIIb and FGFR2-IIIb in LR-MSCs and BM-MSCs. (c) Western blot analysis confirmed that both LR-MSCs 
and BM-MSCs express the protein of FGFR2. (d) Immunofluorescence staining of LR-MSCs and BM-MSCs 
demonstrated expression of FGFR2 on cell membrane. Each point corresponds to the mean ± SEM.
www.nature.com/scientificreports/
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24 h and 48 h, H&E staining of lung sections from MSCs-treated rats had significantly less injury compared with 
rats given PBS (Fig. 8I,j).
At 24 h, the levels of TNF-α , MIP-2, IL-1β and IL-6 in the BAL were not significantly lower in the 
MSCs-treated rats compared with the PBS-treated rats. Surprisingly, IL-6 showed a 3-fold increase in the BAL 
of the LR-MSCs treated rats. At 48 h, TNF-α and MIP-2 levels showed a trend toward being lower in the BAL of 
BM-MSCs treated rats, and were significantly lower in the BAL of the LR-MSCs treated rats. IL-1β and IL-6 levels 
in the BAL were significantly lower in both the BM-MSCs and LR-MSCs groups compared with the PBS group 
(Fig. 8e–h).
Discussion
In this study, we demonstrate that fibroblast-like cells can be isolated with a high yield from the distal airways 
of rats treated with FGF-10. BAL-derived mesenchymal cells exhibited several characteristics similar to classical 
bone marrow-derived MSCs28. First, they can be isolated by adherence purification on tissue culture plastic and 
form distinct CFU-Fs in cell culture. Second, these cells express surface markers typically associated with MSCs, 
but do not express hematopoietic stem cell markers. Third, these cells are multipotent and give rise to adipocytes, 
chondrocytes, and osteocytes. Additionally, the LR-MSCs isolated from FGF-10 pretreated lungs were protective 
against LPS-induced acute lung injury.
Previous studies of sex-mismatched human allografts have demonstrated that MSCs in lungs originate in the 
engrafted organ rather than in the bone marrow9. Furthermore, lung-resident MSCs differ from BM-derived 
MSCs with respect to their cytokine/chemokine gene expression profiles, confirming that these cells are distinct 
from those derived from the bone marrow9. Our data provide further evidence that LR-MSCs are located in 
lungs, and when stimulated with FGF-10 in vivo, these cells proliferate. Transcriptional profiles of LR-MSCs and 
Figure 8. Effects of LR-MSCs and BM-MSCs on LPS-induced acute lung injury. LR-MSCs (BM-MSCs 
as positive control, and PBS as negative control) were intrapulmonary delivered to lungs 4 hours after LPS 
instillation, and the lung injury indices were examined 24 h and 48 h after LPS challenge. (a) Rats given MSCs 
showed a trend toward lower lung wet-to-dry weight ratio at 24 h, and a significant difference at 48 h. (b) BAL 
protein was not significantly reduced in the MSCs groups at 24 h, but significantly reduced in the LR-MSCs 
group at 48 h. (c,d) Total cell counts and absolute neutrophil counts were not different among the three groups 
at 24 h, but were significantly reduced in the LR-MSCs group at 48 h. (e–h) At 24 h, the levels of TNF-α , MIP-2, 
IL-1β and IL-6 in the BAL were not significantly lower in the MSCs-treated rats compared with the PBS-treated 
rats, and contrarily IL-6 showed a 3-fold increase in the BAL of the LR-MSCs treated rats. At 48 h, TNF-α and 
MIP-2 levels showed a trend toward being lower in the BAL of BM-MSCs treated rats, and were significantly 
lower in the BAL of the LR-MSCs treated rats. IL-1β and IL-6 levels in the BAL were significantly lower in both 
the BM-MSCs and LR-MSCs groups compared with the PBS group. (i,j) At both 24 h and 48 h, H&E staining 
of lung sections from MSCs-treated rats had significantly less injury compared with rats given PBS. Each point 
corresponds to the mean ± SEM. *P < 0.05.
www.nature.com/scientificreports/
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BM-MSCs suggest important differences between these cells in terms of cell function and signaling pathways. 
These resident MSCs may thus represent a reservoir of endogenous organ-specific adult progenitor cells with a 
potential role in local tissue homeostasis and repair. When lung was injured, those organ specific progenitor cells 
proliferate and spread to injured area to repair.
Several studies illustrate that FGF-10 pretreatment protects against lung injury from various stresses, includ-
ing bleomycin23, high altitude pulmonary edema24, ischemia reperfusion27, mechanical ventilation26, and LPS25. 
In this study, we illustrate that intratracheal administration of FGF-10 mobilized LR-MSCs, which could easily 
be collected by bronchoalveolar lavage. After collection, these LR-MSCs were cultured in vitro and then intratra-
cheally delivered as cellular therapy to rats after LPS-induced lung injury with substantial beneficial effects. 
BM-MSCs were used as positive control, and PBS as negative control. We showed that at 48 hours, both LR-MSCs 
and BM-MSCs improved LPS-induced lung injury, and LR-MSCs seemed to be more effective than BM-MSCs 
in this scenario.
Although type II cell proliferation, increased surfactant production, reduced endothelial and epithelial apop-
tosis and enhanced macrophage endocytosis have been proposed to explain the therapeutic effects of FGF-10 in 
various animal models; however, the impact of FGF-10 on LR-MSCs could also be a potential mechanism for the 
protective effects of FGF-10 on lung injury. The kinetics of both LR-MSCs mobilization after FGF-10 delivery 
and the peak of the protective effects of direct delivery of FGF-10 to lung injured rats are temporally correlated, 
further suggesting that LR-MSCs mobilization may be one of the key mechanisms through which FGF-10 is lung 
protective.
Numerous studies have shown that MSCs can be protective against lung injury and can aid in lung repair30,31. 
Bone marrow-derived MSCs have been utilized more frequently in animal models illustrating the protective 
effects of MSC. In addition, a phase II trial of MSCs in human acute lung injury is currently underway. However, 
more than 99% of the MSCs injected into the lungs could not engraft, Thus, many studies suggest that paracrine 
mediators (including KGF, PGE2, IL1RA, etc.) secreted by MSCs are responsible for the protective effects during 
acute lung injury31. In contrast to bone marrow-derived MSCs, human lung-derived MSCs have the ability to 
engraft in the lung and to communicate with resident epithelial cells via gap junction communications10. Human 
LR-MSCs demonstrated long-term persistence in the murine lungs in which they were injected and remained 
engrafted in lung tissue up to 6 months after administration10. Both BM-MSCs and LR-MSCs secrete KGF, an 
important epithelial growth factor, suggesting that MSCs, regardless of tissue of origin, can modulate alveolar epi-
thelial cells in a paracrine fashion10,30,31. Our data also demonstrate that BM-MSCs and LR-MSCs are protective 
against LPS induced lung injury when delivered after LPS administration. In addition, it appears that LR-MSCs 
may more effectively treat LPS mediated lung injury, which may be due to their superior ability to engraft.
It was shown that MSCs express FGFR2-IIIb, the receptor of FGF-10, and FGF-10 may activate MSCs by bind-
ing to FGFR2-IIIb. However, in vitro study revealed that MSCs did not proliferate more actively when stimulated 
by FGF-10 (data not shown). It seems that MSCs need the in vivo context to respond to FGF-10 stimulation. 
Further study may focus on the FGF-10 mediated intercellular communication and activation, which might fully 
activate the MSCs located in lungs. In addition, the exact location of LR-MSCs needs to be identified, whether 
it is transformed from Clara cell, type II cell, basal cell or fibroblast like cells from the airways needs further 
exploration.
In summary, this study demonstrates, for the first time to our knowledge, the isolation and characterization 
of LR-MSCs from the lower respiratory tract of adult healthy rats by pretreatment with FGF-10. Identification 
and characterization of these MSCs could represent the first step to understanding the mechanisms of FGF-10 in 
lung injury protection and repair and it also provide a new strategy to collect autologous MSCs for future clinical 
investigation.
Methods
Animals. Male Sprague-Dawley rats, 6–8 weeks old, bred under pathogen free conditions were used in these 
experiments. Animals were maintained in the animal facility at Fudan University with clean, controlled tempera-
ture and independent ventilation environment. The animals had free access to food and water.
Animal treatment. Rats were anesthetized with intraperitoneal injection of chloral hydrate (300 mg/kg), 
and then fixed at a 60° angle on a table in a supine position. A fiber optic light source was placed immediately 
over the neck, and the oropharynx was lifted with forceps, allowing for the direct visualization of the trachea. The 
instillate (FGF-10, PBS, MSCs, or endotoxin) was then injected into the trachea using an 18G catheter attached 
to a 1-ml syringe as preciously described32. FGF-10 (provided by Newsummit Co., Shanghai, China) at a dose of 
5 mg/kg was instilled through the catheter into the lungs of rats. Control animals received equal volume of PBS. 
Three days after FGF-10 or PBS instillation, the rats were sacrificed with an intraperitoneal injection of urethane 
(1.5 g/kg) and exsanguinated through the femoral artery. BAL was then performed immediately through tracheal 
intubation and repeated 5 times, and each time 5 ml medium (4 °C) was slowly infused, after which the fluid was 
slowly withdrawn and reinfused for additional two times. The medium used for BAL consists of DMEM/F12 sup-
plemented with 5% fetal bovine serum (Invitrogen), 100 U/ml penicillin/streptomycin (Invitrogen), and 2.5 ug/ml 
amphotericin B (Invitrogen), 0.02 wt% EDTA (Invitrogen).
For LPS-induced ALI model, rats were intratracheally injected with either 5 mg/kg LPS (Escherichia coli 
O55:B5; Sigma, St. Louis, MO) dissolved in 0.3 ml PBS or vehicle (PBS). After 4 hours, 2 × 106 MSCs (BAL-derived 
or BM-derived (Cyagen Biosciences, CA, USA)) dissolved in 0.3 ml PBS or vehicle (PBS) were instilled through 
the catheter into the lungs of rats. The rats were sacrificed 24 or 48 hours after LPS instillation with an intraperi-
toneal injection of urethane (1.5 g/kg).
www.nature.com/scientificreports/
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Isolation and culture of cells from BAL fluid. Recovered BAL fluid was centrifuged at 800 rpm for 
10 minutes at 4 °C, and the pellets were resuspended and seeded at a density of 1 × 105 mononuclear cells per 
well in 6-well cell culture plate. The cells were maintained in medium consisting of DMEM/F12 supplemented 
with 10% fetal bovine serum (Invitrogen), 2 mmol/l L-glutamine (Invitrogen), 100 U/ml penicillin/streptomycin 
(Invitrogen), and 2.5 ug/ml amphotericin B (Invitrogen) and incubated at 37 °C in 5% CO2/95% air. Medium was 
changed first after 24 hours and then every 3 days. Single separated fibroblastoid colonies termed CFU-Fs were 
identified 14 days after initial plating. For staining and enumeration of CFU-Fs, adherent CFU-Fs colonies were 
fixed with 10% formaldehyde and stained with Wright-Giemsa stain (Jiancheng, Nanjing, China). To study mes-
enchymal cells obtained from an individual rat, all colonies growing in 6-well cell culture plate were trypsinized 
and passed into a 100-mm plate. A homogeneous population of mesenchymal cells was obtained from individual 
rats after 3–5 passages.
Assays for adipogenic, chondrogenic, and osteogenic differentiation. Multilineage differentiation 
to adipocyte, chondrocyte, and osteocyte lineages was tested in BAL-derived CFU-Fs at passage 5 using the rat 
mesenchymal stem cell functional identification kit (R&D systems, Minneapolis, MN, USA) according to the 
manufacturer’s instructions. Briefly, for adipogenic differentiation, confluent cell cultures in a 24-well plate were 
treated with adipogenic differentiation medium. At 3 weeks cells were fixed with 10% formaldehyde and incu-
bated with fresh oil red O, lipid droplets were visualized and photographed. Immunofluorescence staining for 
FABP4 using anti-rat FABP4 antibody was performed to demonstrate adipogenic differentiation. Osteogenic dif-
ferentiation was induced by incubating the cells with osteogenic differentiation medium. After 21 days, cells were 
fixed and incubated with freshly made 2% alizarin red stain. Immunofluorescence staining for osteocalcin using 
anti-rat osteocalcin antibody was performed to demonstrate osteogenic differentiation. For chondrogenic dif-
ferentiation, cells were cultured as a pelleted micromass in chondrogenic differentiation medium. After 4 weeks, 
pellets were embedded en bloc in OCT, and 6-μ m frozen sections were obtained. The sections were stained with 
H&E, and immunofluorescence staining for the extracellular matrix proteoglycan aggrecan using anti-rat aggre-
can antibody was performed to demonstrate chondrocyte differentiation.
Multiparameter flow cytometric analyses (FACS). Cell-surface antigen phenotyping was performed 
on cell lines generated from individual rats at passage 5 using antibodies against CD34 (Santa Cruz, sc-7324), 
CD45 (eBioscience, 17-0461-80), CD29 (BioLegend, 102206), CD73 (BD, 551123), and CD90 (eBioscience, 
12-0900-81). Briefly, cells were trypsinized and aliquoted at a concentration of 0.5 × 106 cells/ml and stained for 
30 minutes with either conjugated specific antibodies or isotype-matched control IgGs at recommended concen-
trations. Labeled cells were washed twice, resuspended in FACS buffer, and analyzed on flow cytometer (BD).
Immunofluorescence staining. Immunofluorescence labeling was performed at passage 5 using mouse 
mAb against CD105 (Santa Cruz, H-300), vimentin (Cell Signaling Technology, R28), AQP5 (Abcam, ab78486), 
and FGFR2 (Abcam, ab10648). Cells were visualized and photographed using an Olympus confocal fluorescence 
microscope.
RNA isolation and analysis. Total  RNA was isolated from mesenchymal stem cel ls 
using the RNeasy Mini Kit  (QIAGEN) as per the manufacturer’s  instructions.  Real-t ime 
PCR was performed for expression of FGFR1-IIIb and FGFR2-IIIb using the primers as 
previously described33. Primers for FGFR1-IIIb: forward 5′-CGGGGATTAATAGCTCGGATG-3′, reverse 
5′-GCACAGGTCTGGTGACAGTGA-3′. Primers for FGFR2-IIIb: forward 5′-GAGCACCGTACTGG 
ACCAACAC-3′, reverse 5′-TGGTAGGTGTGGTTGATGGACC-3′. β -Actin was used as a control, 
and the primers were forward 5′-GGAGATTACTGCCCTGGCTCCTA-3′, and reverse 5′-GACTCAT 
CGTACTCCTGCTTGCTG-3′. The PCR reactions were carried out for 45 cycles with the primer sequences. The 
reaction products were resolved by electrophoresis on a 1.0% agarose gel and visualized with ethidium bromide. 
Further sequencing was performed to validate the PCR products.
For Affymetrix analysis, BM-MSCs were isolated from the normal rat bone marrow as previously described34. 
Total RNA was prepared from 3 sets each of bone marrow- and BAL-derived MSCs cultured under similar con-
ditions at passage 5. Affymetrix array hybridization and scanning were performed by the Affymetrix and cDNA 
Microarray Core Facility at the Qiming biotech co., using Rat Gene 1.0 ST chips. Expression values for each 
gene were calculated using a robust multiarray average algorithm and expressed as log2-transformed data. Gene 
Ontology analysis was used to determine differential functions and signaling pathways between lung-derived and 
bone marrow-derived MSCs.
EdU incorporation assay. EdU (5-ethynyl-2′ -deoxyuridine) (Invitrogen) was injected intraperitoneally 
(100 mg/kg) to FGF-10 pretreated rats 24 hours before BAL, and the MSCs in BAL fluid were isolated and cultured 
for 5–7 days, then were detected for EdU incorporation according to manufacturer’s recommendations.
Western blot analysis. Cells and homogenized lung tissue were lysed by RIPA and 20 μ g of protein were 
electrophoresed. Membranes were exposed overnight at 4 °C to rabbit anti-FGFR2 polyclonal antibody (Abcam, 
ab10648) diluted 1:2000 or anti-β -actin antibody (Abcam, ab8227) diluted 1:1000 as loading control, then incu-
bated for 1 h with horseradish peroxidase-conjugated goat anti-rabbit IgG antibody (Jackson ImmunoResearch, 
USA) diluted 1:20000.
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Wet-to-dry weight ratio. The right main bronchus was ligated, and the right lungs were excised. After wet 
weights were measured, the middle lobe of the right lung were placed in an oven at 60 °C for 72 h to allow deter-
mination of the wet-to-dry weight ratio.
Bronchoalveolar Lavage. The bronchoalveolar lavage (BAL) was performed in the left lung. 2 ml PBS 
(4 °C) was slowly infused, after which the fluid was slowly withdrawn and reinfused for additional two times. The 
recovered fluid was collected for further analysis.
Total cell count and differential cell count. BAL fluid (BALF) samples were centrifuged at 1200 rpm 
for 10 min at 4 °C, the supernatant was removed and stored at − 80 °C. The pellet was resuspended in 0.5 ml of 
PBS. The total number of nucleated cells in BAL fluid was counted with a hemocytometer. Then the resuspended 
BAL fluid was centrifuged onto slides (1800 rpm for 15 min) and stained with Wright-Giemsa stain (Jiancheng, 
Nanjing, China). The slides were quantified for neutrophils number by counting a total of 200 cells per slide.
BALF protein concentration. BALF protein concentration was measured using a bicinchoninic acid 
(BCA) protein assay kit according to the manufacturer’s instruction (Thermo Fisher Scientific, MA, USA).
Cytokines in BALF. TNF-α , IL-1β , IL-6, and MIP-2 levels in BALF were measured using rat TNF-α , IL-1β , 
IL-6, and MIP-2 ELISA kits (R&D Systems, Minneapolis, MN) according to the manufacturer’s recommenda-
tions, respectively.
Lung morphometry analyses. Histopathologic changes induced by LPS were evaluated in rats pretreated 
with MSCs or vehicle. The lungs were fixed with 10% formalin, and 5 μ m sections were cut for H&E staining. The 
injury degree was scored with the following criteria: 1, no injury; 2, injury to 25% of the field; 3, injury to 50% of 
the field; 4, injury to 75% of the field; 5, diffuse injury25. All samples were examined by 3 pathologists blinded to 
the experimental procedures and the mean score was used.
Statistics. Each point corresponds to the mean ± SEM. Statistical differences were determined using the 
one-way analysis of variance (ANOVA), and p < 0.05 was considered significant. Individual groups were com-
pared using the unpaired Student’s t test.
Study approval. All experimental protocols were approved by the Institutional Animal Care and Use 
Committee of Zhongshan Hospital, Fudan University. All animals were handled in accordance with the Guide for 
the Care and Use of Laboratory Animals published by the National Institutes of Health, and efforts were made to 
minimize suffering and pain of the animals, and number in each group in our study.
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